Please use this identifier to cite or link to this item:
|Title:||New therapeutic targets in the treatment of age-related macular degeneration.|
|Other Titles:||Nuevas dianas terapéuticas en el tratamiento de la degeneración macular asociada a la edad.|
Age related macular degeneration
Antibodies, Monoclonal, Humanized
Platelet-Derived Growth Factor
Recombinant Fusion Proteins
|Citation:||Arch Soc Esp Oftalmol (Engl Ed).2020;(95)2:75-83|
|Abstract:||Age-related macular degeneration and especially neovascular age-related macular degeneration is the leading cause of low vision in developed countries. Even though the introduction of anti-VEGF drugs in recent years completely changed the management of this condition, its cost, the need for repeated intravitreal injections, and loss of efficacy in the long term are still issues to deal with. Currently, a new generation of novel therapies under development is attempting to address some of these limitations. Some of the most prominent among them are new anti-VEGFs such as brolucizumab or abicipar, drugs against angiopoietin-2 receptor such as faricimab, sustained-release systems, or tyrosine kinase inhibitors. As regards dry age-related macular degeneration, neuroprotection, the complement pathway, and stem cell therapy are the most promising targets currently under investigation.|
|Appears in Collections:||Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos|
Files in This Item:
The file with the full text of this item is not available due to copyright restrictions or because there is no digital version. Authors can contact the head of the repository of their center to incorporate the corresponding file.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.